After nearly two decades of research, a biotech company was on the verge of bringing its pioneering anti-Alzheimer’s vaccine to market. Their objective was to attract investors, Big Pharma, and secure critical grant funding.
Our Approach:
- Showcasing Innovation: We delivered compelling narratives around the company’s scientific approach to the industry media.
- Amplifying Visibility: We strategically increased the volume of news and updates to keep the company top-of-mind for potential investors.
- Thought Leadership: We facilitated high-profile media interviews for the founders, strengthening their personal brands.
- Expert-Driven Content: We developed insightful op-eds to position founders as leading voices in the fight against Alzheimer’s.
Media Coverage Highlights: Forbes, Science Times, BioSpace, Pharma Times